Benign Prostatic Hypertrophy Pleads for Ablative Therapy

Excerpt from “Worldwide Ablation Technologies”, report #A125 from MedMarket Diligence.

An estimated one third of men older than 50 years develop symptoms of prostate enlargement, and 30% of these men eventually require surgery. Some 50% of men have histologic evidence of BPH by the age of 50 years, which increases to 75% in men older than 80 years. In 40-50% of these patients, BPH becomes clinically significant. Adenomatous growth is believed to begin in persons younger than 30 years.

Untreated, BPH can lead to significant morbidity due to physical obstruction of urinary outflow. Urinary stasis leads to an increased risk of urinary tract infections and urosepsis, detrusor dysfunction, bladder stones, and renal failure. As the population ages, a greater number of men are presenting with benign prostatic hypertrophy (BPH). The standard for treatment of BPH is the transurethral resection of the prostate (TURP). While, in general, this procedure is safe, patients require a spinal, epidural, or general anesthesia and several days of hospital stay. The potential morbidity and mortality limits the use of TURP in patients at high surgical risk. Over the past decade, the popularity of TURP has steadily declined, with an estimated 140,000 to 150,000 performed annually in the USA.

Due to the potential for ablative therapies compared to TURP, treatment of BPH nearly pleads for ablative therapy, which can be accomplished by these less-invasive surgeries now accounting for about 40,000 to 50,000 procedures annually. This group includes a variety of procedures, such as transurethral needle ablation (TUNA), transurethral microwave thermotherapy (TUMT), interstitial laser coagulation (ILC) and high-frequency ultrasound (HIFU). Recently, several new procedures and devices have been created and evaluated in an attempt to relieve bladder outlet obstruction and to improve urinary flow; these new methods include TUMT, transurethral laser incision of the prostate (TULIP), and transurethral needle ablation (TUNA), and each of these methods is associated with benefits and risks.

A competitive market is evolving for alternative BPH treatment:

  • TUMT
  • TUNA
  • Photoselective Vaporization of the Prostate
  • HoLAP
  • ILC
  • CoreTherm
  • TMX 3000
  • Prolieve
  • Prostiva RF Therapy
  • Water-Induced Thermotherapy (WIT)

Below are a selection of companies focused on the use of ablative therapies for treatment of BPH and/or prostate cancer:

  • ACOUSTx
  • Accuray
  • American Medical Systems
  • Angiodynamics
  • EDAP TMS S.A.
  • Endocare
  • Erbe Elektromedizin
  • Galil Medical
  • HealthTronics Surgical Services
  • Misonix
  • Theragenics Corporation
  • USHIFU
  • Varian Medical Systems

This report is described in detail at link. The report is available for immediate download via purchase online or may be purchased via Google Checkout, below.

1 thought on “Benign Prostatic Hypertrophy Pleads for Ablative Therapy”

Leave a Reply